What’s the best way to introduce AI to enhance automation of high-volume pharmacovigilance activities, such as adverse event case intake and processing?
Claudia Lehman, head of global pharmacovigilance operations at Boehringer Ingelheim and Lucinda Smith, ArisGlobal’s chief safety product officer, reflect on the critical success factors.